Pharmesis International Ltd
SGX:BFK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Better Collective A/S
STO:BETCO
|
DK |
Pharmesis International Ltd
Accounts Receivables
Pharmesis International Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pharmesis International Ltd
SGX:BFK
|
Accounts Receivables
¥16.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Accounts Receivables
¥3.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Accounts Receivables
¥5.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
9%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Accounts Receivables
¥10.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
23%
|
CAGR 10-Years
25%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Accounts Receivables
¥3.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Accounts Receivables
¥106.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
Pharmesis International Ltd
Glance View
Pharmesis International Ltd. is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2004-10-06. The firm is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. The company operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.
See Also
What is Pharmesis International Ltd's Accounts Receivables?
Accounts Receivables
16.1m
CNY
Based on the financial report for Dec 31, 2025, Pharmesis International Ltd's Accounts Receivables amounts to 16.1m CNY.
What is Pharmesis International Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
-3%
Over the last year, the Accounts Receivables growth was -55%. The average annual Accounts Receivables growth rates for Pharmesis International Ltd have been 11% over the past three years , 8% over the past five years , and -3% over the past ten years .
